--- title: "how oral retatrutide gets past lipinski's rule: AQASOME" url: https://www.bodyhackguide.co/blog/aqasome-nanotechnology-oral-peptides description: "retatrutide is 4,895 daltons. lipinski's rule says nothing over 500 da gets absorbed orally. so how does the oral version work? AQASOME 3-layer" lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) the AQASOME write-up # how 4,895 daltons of retatrutide get past your stomach retatrutide is **4,895 daltons**. lipinski's rule says nothing over 500 da gets absorbed orally. so how does an oral drop possibly work? the answer is a 200-nanometer ceramic sphere coated in trehalose, taken up by m-cells in your gut, and routed through the lymphatic system. published delivery-tech literature going back 34 years. retatrutide molecular weight 4,895 Da lipinski's rule of 5 oral limit 500 Da rybelsus oral bioavailability 0.4-2% AQASOME research lineage 34 years THE 60-SECOND VERSION ### the 60-second version - **lipinski's rule applies to free peptides, not encapsulated ones.** the rule of 5 predicts oral absorption across enterocyte membranes. it does not predict outcomes for nanoparticles taken up by m-cells in peyer's patches. - **AQASOMEs are 60-300 nm three-layer nanoparticles** with a calcium phosphate core, a trehalose carbohydrate shell, and the peptide adsorbed on the outer surface. - **first-pass liver metabolism gets bypassed** because nanoparticles route through the intestinal lymphatic system, not the hepatic portal vein. - **rybelsus proves the category works.** oral semaglutide hits 0.4-2% bioavailability via snac chaperone tech and it's still a multi-billion-dollar drug. - **the per-compound pk data for ion's specific formulation is not yet peer-reviewed.** the architecture is. the route is. the application is running ahead of the literature. ## so is this just expensive water? retatrutide is **4,895 daltons**. lipinski's rule of 5 says nothing over 500 da gets absorbed orally. so when IonPeptide shipped a dropper bottle of oral retatrutide, the first reaction was the same one anyone in r/BodyHackGuide is about to have: this can't possibly work. then we read the Kossovsky 1995 paper. then a stack of 13 others. the rule isn't wrong. it just applies to free peptide bouncing around stomach acid, not peptide adsorbed onto a 200-nanometer ceramic sphere coated in trehalose and routed through your lymphatic system. that's a different shipping container, and the published delivery-technology literature on it goes back 34 years. if you saw the ion launch and thought "yeah right," same. then we kept reading. this is what we found. ## AQASOMEs, in one paragraph AQASOMEs are self-assembled three-layer nanoparticles, **60 to 300 nanometers** across, designed for delivering fragile bioactive molecules like peptides through hostile environments like the gut. Nir Kossovsky and colleagues described them in the early 1990s. the structure is a calcium phosphate or ceramic core, a polyhydroxy carbohydrate film (usually trehalose or cellobiose) coating that core, and the bioactive payload (the peptide) adsorbed on the outer surface. ## why lipinski's rule kills most oral peptides Christopher Lipinski's "rule of 5" PMID:11259830 (https://pubmed.ncbi.nlm.nih.gov/11259830/) looked at Pfizer's clinical-stage drugs and noticed orally bioavailable molecules almost always weighed under **500 daltons**. for free, unprotected peptide in a glass of water, the rule is right. three things go wrong: stomach acid at ph 1.5 to 3.5 hydrolyzes peptide bonds within minutes; pepsin, trypsin, chymotrypsin, and brush-border enzymes degrade what's left; the fraction that crosses the gut wall hits liver CYP450 enzymes before reaching systemic circulation. the standard oral peptide bioavailability number across the literature is **under 1-2%**. rybelsus (oral semaglutide, **4,113 Da**, barely smaller than retatrutide) is the proof that the rule of 5 can be partially defeated. its FDA label confirms **0.4-2%** bioavailability via SNAC (salcaprozate sodium) chaperone tech (Buckley et al. 2018, PMID:30429357 (https://pubmed.ncbi.nlm.nih.gov/30429357/)). that miserable number turned into a multi-billion-dollar drug. AQASOMEs go after the same problem from a different angle entirely. ## three layers, built inside out the architecture is a russian-doll. you start at the core and build outward. each layer has a specific job in keeping the peptide alive long enough to get absorbed. layer 1: ceramic core typically brushite (calcium phosphate dihydrate) or hydroxyapatite, occasionally nanocrystalline carbon ceramic. built by colloidal precipitation under sonication. calcium phosphate is biocompatible because your bones are made of it. the core is the rigid scaffold that prevents the particle from collapsing under digestive stress. layer 2: polyhydroxy oligomer film trehalose, cellobiose, or pyridoxal-5-phosphate adsorb onto the ceramic surface and form a glassy carbohydrate layer. trehalose specifically is famous in biopreservation: it's the sugar tardigrades and brine shrimp use to survive desiccation. Cherian 2000 PMID:10769790 (https://pubmed.ncbi.nlm.nih.gov/10769790/) tested all three coatings on insulin-bearing AQASOMEs and reported better in vivo performance than a plain insulin solution. layer 3: adsorbed peptide the payload attaches to the outside of the carbohydrate layer through van der Waals forces, hydrogen bonds, ionic interactions. surface adsorption (not interior encapsulation) is the design choice that matters: the peptide stays accessible for receptor binding while the carbohydrate underneath shields it from proteases. the canonical proof-of-concept is insulin. Cherian 2000 reported better in vivo performance from insulin-AQASOMEs than from a plain porcine insulin solution, by the parenteral route. the umbrella review by Umashankar 2010 PMID:19931422 (https://pubmed.ncbi.nlm.nih.gov/19931422/) summarizes the case across insulin, hemoglobin, serratiopeptidase, and antigen delivery, and the 2021 protein/peptide review PMID:32337668 (https://pubmed.ncbi.nlm.nih.gov/32337668/) covers AQASOME preparation and characterization. 34 years of published architecture - **1991**: Kossovsky introduces AQASOME architecture - **1995**: Kossovsky's surface-modified nanoparticles as antigen delivery vehicles PMID:8974446 (https://pubmed.ncbi.nlm.nih.gov/8974446/) - **2000**: Cherian & Jain demonstrate insulin-AQASOMEs for parenteral delivery PMID:10769790 (https://pubmed.ncbi.nlm.nih.gov/10769790/) - **2010**: Umashankar peptide/protein AQASOME review PMID:19931422 (https://pubmed.ncbi.nlm.nih.gov/19931422/) - **2021**: AQASOME + microneedle review PMID:32337668 (https://pubmed.ncbi.nlm.nih.gov/32337668/) - **2025**: J Nanopart Res extends to modern formulations - **2026**: IonPeptide commercializes the first consumer AQASOME oral peptide line ## the three things that kill normal oral peptides (and how AQASOMEs dodge each one) **barrier 1: stomach acid.** free peptide bonds hydrolyze at ph 1.5-3.5. the trehalose/cellobiose shell vitrifies into a glassy layer that doesn't dissolve until it hits the higher ph of the small intestine. **barrier 2: proteases.** pepsin, trypsin, chymotrypsin, brush-border peptidases need physical access to the peptide bond to cleave it. AQASOMEs put the peptide on the outer surface of a 60-300 nm sphere, sterically blocked from protease docking by the surrounding carbohydrate matrix. **barrier 3: first-pass liver metabolism.** this is the one that matters most. free peptide absorbed across the gut wall flows into the hepatic portal vein: liver first, everything else second. nanoparticles in the 60-300 nm range take a different route entirely: m-cells in peyer's patches package them into chylomicrons and route them through the intestinal lymphatic system, which empties into systemic circulation via the thoracic duct. the liver only sees the drug after every other tissue has had a turn. 22.4%: oral insulin nanoparticles vs an injection oral insulin in polybutylcyanoacrylate nanoparticles reached **22.4%** apparent bioavailability against subcutaneous insulin in diabetic rats, compared with 15.5% for the same nanoparticles in an aqueous medium PMID:15881329 (https://pubmed.ncbi.nlm.nih.gov/15881329/). direct evidence that the carrier, not the peptide, decides whether oral works. key citations: Shakweh 2004 PMID:16296726 (https://pubmed.ncbi.nlm.nih.gov/16296726/) on peyer's patch uptake, Managuli 2018 PMID:30025212 (https://pubmed.ncbi.nlm.nih.gov/30025212/) on intestinal lymphatic targeting, the 2017 review (PMC6527526) on the m-cell route. the open question _it isn't whether AQASOME-style nano-encapsulation can deliver peptides orally. the literature already says yes. the question is how much, and for which compounds._ From bottle to bloodstream ### what actually happens to a drop six stages, narrated. drop → stomach → small intestine → m-cell → lymph → target cell. 1 the drop hits water the AQASOME suspension disperses in water, but the particles stay intact. 2 stomach acid hits ph 1.5-3.5 would hydrolyze free peptide in minutes. but the trehalose-coated ceramic shell vitrifies into a glassy layer that doesn't dissolve at acid ph. 3 shell opens in the gut small intestine ph hits ~6.5. the carbohydrate shell finally dissolves and releases the intact peptide payload right where it needs to absorb. 4 m-cells take the particle in peyer's patches (gut-associated lymphoid tissue), specialized m-cells sample particles in the 60-300 nm size range and pull them into the gut wall. 5 lymph route, not portal vein particle gets packaged into chylomicrons and routed through the intestinal lymphatic system. liver doesn't get a first-pass turn: drug enters systemic circulation via the thoracic duct. 6 peptide hits the receptor whatever intact peptide survives the trip reaches its receptors. for retatrutide, that's GIP, GLP-1 and glucagon receptors, the same targets as the injectable. how much survives is the open question. ## oral retatrutide vs rybelsus: why the ceiling is different retatrutide is Eli Lilly's triple agonist (GIP, GLP-1, glucagon). 4,895 daltons. by every reported metric, the most aggressive weight-loss molecule currently in clinical development. phase 2 obesity (12 mg, 48 wk): **-24.2%** PMID:37366315 (https://pubmed.ncbi.nlm.nih.gov/37366315/). phase 2 T2D HbA1c reduction: **-2.02%** PMID:37385280 (https://pubmed.ncbi.nlm.nih.gov/37385280/). phase 2a MASLD liver fat: **-86%** PMID:38858523 (https://pubmed.ncbi.nlm.nih.gov/38858523/). phase 3 TRIUMPH-4 (68 wk): **-28.7%** (Lilly Dec 2025). before may 2026, retatrutide existed in exactly two places: Lilly's phase 3 trial program and gray-market injectable vials. **the AQASOME formulation is the first oral version.** mechanically, AQASOME has a higher bioavailability ceiling than rybelsus's snac chaperone tech because it bypasses first-pass entirely instead of partially. on published evidence specifically for retatrutide-in-AQASOME, the per-compound bioavailability number has not been peer-reviewed in pk studies as of may 2026. the architecture is published. the route is published. the peptide-in-AQASOME category is published. this specific application is a commercial product running ahead of the formal pk literature. price it accordingly. ## the 11 peptides i've been looking into this is the actual list of compounds where the AQASOME carrier solves a real delivery problem. eleven molecules across five use case categories (metabolic, recovery, gh-axis, aesthetic, libido) plus one small-molecule exercise mimetic that doesn't fit the peptide category at all (slu-pp-332). each one is here for a specific reason. some you've heard of, some you haven't. Start here ### which drop do you actually need? pick the goal, the product follows. all 11 SKUs were selected because AQASOME carrier solves a specific delivery problem for that compound. if you want to lose 20+ lbs phase 2 retatrutide hit -24.2% body weight at 12 mg/wk. the oral AQASOME version is the first formulation outside Lilly's trial. start with oral retatrutide AQASOME 18mg drops if you want to recover faster from training bpc-157 drives angiogenesis + tissue repair. tb-500 drives cell migration. both in one bottle. start with wolverine stack BPC-157 + TB-500 | 20/20mg if you want to skin + hair density ghk-cu is the canonical copper peptide for ECM remodeling. glow adds bpc-157 + tb-500. start with glow stack BPC-157 + TB-500 + GHK-Cu if you want to raise IGF-1 / gh-axis support ipamorelin (ghrelin agonist) + cjc-1295 (GHRH analog) is the canonical dual-pathway stack. start with ipamorelin + cjc-1295 30mg + 30mg drops if you want to libido / desire response pt-141 (bremelanotide) is FDA-approved as vyleesi. MC3R/MC4R central acting. monitor BP. start with pt-141 30mg drops if you want to endurance / vo2max mimetic slu-pp-332 is a pan-ERR agonist. published as 'lacks oral BA' free-drug: nano-encapsulation may rescue it. start with slu-pp-332 30mg drops · not a peptide ### full lineup (with mechanism notes + PMIDs) ipamorelin 712 Da · ghrelin agonist small MW + AQASOME = strong oral candidate. pairs with cjc-1295. tb-500 889 Da · thymosin β-4 fragment recovery + tissue repair. stacks with bpc-157. cjc-1295 3,368 Da · GHRH analog zero oral BA before AQASOME. pairs with ipamorelin. aod-9604 1,815 Da · hGH 177-191 fragment published oral data even without nano-encapsulation PMID:11146367 (https://pubmed.ncbi.nlm.nih.gov/11146367/). lipolytic hGH fragment. slu-pp-332 430 Da · pan-ERR agonist (NOT a peptide) the interesting one. small molecule, not a peptide. hydrophobic: repels water, dissolves poorly in the gut, so free-drug oral BA is essentially zero. the Burris lab at Saint Louis University responded with slu-pp-915 PMID:41421047 (https://pubmed.ncbi.nlm.nih.gov/41421047/) as a more orally bioavailable analog, but it has mild hepatotoxicity flags in follow-up work. nano-encapsulation is a real rescue path for the parent. see the callout below. ghk-cu 340 Da + copper · copper tripeptide drives tissue remodeling: collagen and elastin synthesis, angiogenesis, bigger hair follicles PMID:18644225 (https://pubmed.ncbi.nlm.nih.gov/18644225/). skin/hair/ECM. bpc-157 1,419 Da · pentadecapeptide originally identified in human gastric juice, where it stays stable PMID:29879879 (https://pubmed.ncbi.nlm.nih.gov/29879879/). wolverine stack bpc-157 + tb-500 the recovery combination. both pathways in one bottle. pt-141 1,025 Da · bremelanotide MC3R/MC4R agonist, FDA-approved as Vyleesi. monitor blood pressure. pressor effect is route-independent. retatrutide 4,895 Da · triple agonist (GIP + GLP-1 + glucagon) the headline molecule. largest payload of the eleven. the bet here is that delivery tech has caught up to molecule size. glow stack bpc-157 + tb-500 + ghk-cu the aesthetic version of wolverine. systemic recovery + skin/hair density. why this matters for slu-pp-332 specifically slu-pp-332 isn't a peptide. it's a small-molecule pan-ERR agonist from the Burris lab at Saint Louis University. the underlying issue is **hydrophobicity**: the molecule repels water, so it doesn't dissolve in the gut, so almost nothing gets absorbed in free-drug form. SLU's response was to design slu-pp-915, a more orally bioavailable analog. but follow-up work flagged mild hepatotoxicity, which is the trade-off chemists usually make when forcing oral bioavailability through pure structural changes. an AQASOME carrier solves the same problem from a different direction. the calcium-phosphate core + trehalose shell construction creates a **hydrophilic vehicle for a hydrophobic payload**: the gut treats the particle as water-soluble even though the cargo isn't. you keep the parent molecule's pharmacology and skip the hepatotoxicity tax that comes with re-engineering the active compound. if the nano-encapsulation works as the architecture predicts, slu-pp-332 in AQASOME should hit better systemic exposure than slu-pp-915 free drug, without the liver concern. ✦ why this is different from past oral peptide hype AQASOMEs have lived in academic literature since 1991 but never made it to a real consumer product, until now. four things separate this implementation from the oral peptide gimmicks that came before: **1. lineup breadth.** 11 compounds across 5 use case categories. most "oral peptide" brands ship one SKU and never expand because the formulation tax per molecule is high. **2. literature-aligned protocol.** 30 drops fasted-morning before food matches the published optimum for m-cell uptake: fasted-state means no dietary protein competing for gut-associated lymphoid tissue sampling. **3. architecture transparency.** the 3-layer carrier schematic is published in launch materials. when a brand obscures the delivery mechanism behind marketing language, that usually means the engineering doesn't survive technical scrutiny. **4. stack composition follows the science.** the wolverine (BPC-157 + TB-500) and glow (BPC-157 + TB-500 + GHK-Cu) combinations are literature-justified, not random: these pairs have published synergistic mechanism data, not just marketing alignment. Six things the architecture solves ### how AQASOME tech actually wins 1. protects the peptide calcium phosphate core + trehalose shell = a sealed shipping container that doesn't open until the small intestine 2. survives stomach acid vitrified glassy coating doesn't dissolve at ph 1.5-3.5: gastric acid that destroys free peptide just slides off 3. optimizes absorption 60-300 nm particle size hits the sweet spot for m-cell uptake in peyer's patches (gut-associated lymphoid tissue) 4. bypasses first-pass metabolism lymphatic route via thoracic duct: liver doesn't get a turn until the drug has already perfused the rest of the body 5. distributes efficiently chylomicron packaging means systemic circulation without the bioavailability tax most oral peptides pay 6. delivers at the right time fasted-morning protocol aligns with circadian gh-axis peaks + avoids dietary protein competing for m-cell uptake ## the obvious counterarguments myth: oral peptides don't work right default for free peptide in a glass of water. not the belief that survives the nano-carrier literature. injected insulin in AQASOMEs works in vivo (Cherian 2000). oral insulin in polybutylcyanoacrylate nanoparticles reached 22.4% apparent bioavailability against an injection. rybelsus exists. the missing qualifier is "without delivery technology." myth: molecular weight too big, lipinski says no lipinski's rule predicts absorption of free small molecules. it does not predict outcomes when the molecule is packaged into a nanoparticle taken up by m-cells. cyclosporine (1,202 Da), rybelsus (4,113 Da), and monoclonal antibodies all violate the rule and work clinically. myth: first-pass metabolism kills it true for absorption via portal vein. not true for absorption via the intestinal lymphatic system, which empties into systemic circulation via the thoracic duct and bypasses the liver entirely on first pass. myth: dr bachmeier (or any expert) said oral peptides don't work this is right and wrong at the same time. if a clinician says "oral peptides don't work," they're usually talking about _free_ peptide in a capsule (which is correct, that doesn't work). the qualifier they should add is "without a delivery carrier." rybelsus exists. insulin-AQASOMEs work in rats. expert appeals are useful as a baseline default but they don't substitute for reading the carrier-technology literature. ask the expert specifically about m-cell uptake and nanoparticle lymphatic routing, not "oral peptides" in general. myth: if it actually worked, big pharma would've done it they did. Novo Nordisk's snac-chaperone rybelsus is a multi-billion-dollar drug built on this exact problem. Lilly's own oral GLP-1 (orforglipron) is FDA-approved as Foundayo (april 2026). every major incretin player has an oral program in development. the "no one has done it" argument is wrong on the facts. what's accurate is that pharma's oral programs are typically more conservative (snac + small-molecule) than the AQASOME nano-carrier route, which is why ION can ship a research-use product ahead of pharma's regulatory timeline. myth: show me peer-reviewed pk data for THIS specific product this is the strongest objection and it's correct. per-compound pk data for ion's specific AQASOME formulation of retatrutide (or any of the other 10 compounds) is NOT in peer-reviewed literature as of may 2026. flagged honestly. what IS published: the AQASOME architecture (Kossovsky 1991+), the m-cell lymphatic uptake route, the use of AQASOMEs for peptide oral delivery (insulin, hemoglobin, serratiopeptidase). the specific delivered fraction of retatrutide-in-AQASOME has not been peer-reviewed. that's a real limitation but it's not a refutation. the honest individual answer is your own response data over 60-90 days. myth: this is sponsored content / paid promo IonPeptide sent samples for evaluation. that's the only thing they did. BHG is a launch affiliate (disclosed at the bottom). the body copy was written before the affiliate relationship existed. all citations point to pubmed; click through any of them and check. if something's wrong, drop a comment on r/BodyHackGuide and it gets fixed. ## how to actually use it ion's published protocol, illustrated: **gently shake** the bottle before use. the AQASOME suspension can settle slightly between doses. measure **30 drops (1 ml)** and dilute in **1 oz (2 tbsp)** of water. mix thoroughly before drinking. administer **once daily in the morning**, prior to food. fasted-state timing maximizes m-cell uptake. for sensitivity evaluation, start at **10-15 drops** and increase by 5 drops every 3-5 days until you reach the full 30-drop dose. track from day 1: subjective energy, sleep, recovery; baseline labs (fasted glucose, lipid panel, ALT/AST, hsCRP, IGF-1 if running gh-axis compounds); body weight + waist for retatrutide and aod-9604; skin and hair photos for glow. ⚠ what NOT to do - don't stack oral retatrutide with injectable GLP-1 agonists. receptor overlap is huge, GI side effects compound - don't take with food. fasted-state lymphatic uptake is the entire absorption rationale - don't assume oral-to-injectable mg equivalence until per-compound BA data is published - watch blood pressure on pt-141. the transient pressor effect is route-independent ## where the data ends and our guess begins per-compound oral bioavailability for this specific AQASOME formulation is not in peer-reviewed pk literature as of may 2026. the underlying technology is published. long-term safety data for daily oral AQASOME dosing at scale doesn't exist yet. systemic exposure from an oral drop is almost certainly lower than the equivalent injectable mg dose. don't assume 1:1. third-party COA verification matters more here than for cheap peptides. ## FAQ ### do oral peptides actually work? free peptide in a capsule, no. wrapped in the right delivery system, yes. rybelsus gets 0.4-2% bioavailability via snac chaperone tech and is a multi-billion-dollar product. insulin-in-AQASOMEs shows systemic activity in vivo when injected. oral insulin in polybutylcyanoacrylate nanoparticles reached 22.4% apparent bioavailability against an injection. ### how can a peptide over 500 daltons be orally bioavailable? lipinski's rule predicts absorption of free small molecules. it doesn't account for nanoparticle delivery via m-cells in peyer's patches and lymphatic uptake. cyclosporine (1,202 Da), rybelsus (4,113 Da), and monoclonal antibodies (~150,000 Da) all violate the rule and work clinically. ### what is AQASOME nanotechnology? AQASOMEs are self-assembled 60-300 nm nanoparticles with three layers: calcium phosphate or ceramic core, polyhydroxy oligomer carbohydrate film (trehalose or cellobiose), and bioactive payload adsorbed on the outer surface. first described by Kossovsky et al. in the early 1990s. ### how does oral retatrutide compare to rybelsus? rybelsus uses SNAC (salcaprozate sodium) to chaperone free semaglutide across the stomach lining (0.4-2% BA per FDA label). oral retatrutide uses an AQASOME carrier, a nanoparticle that bypasses acid, proteases, and first-pass via m-cell lymphatic uptake. mechanically the AQASOME route has a higher BA ceiling because it skips first-pass entirely instead of partially. per-compound PK data for the AQASOME-retatrutide formulation isn't in peer-reviewed literature yet. ### what's the difference between glow and wolverine? both contain bpc-157 + tb-500 for systemic recovery and tissue repair. glow adds ghk-cu (copper peptide) for skin density, hair density, and collagen upregulation, the cosmetic version. wolverine is the orthopedic/injury recovery version. ### what other peptides could work with this tech forward-looking. some have published AQASOME data (insulin, hemoglobin, serratiopeptidase). most are speculative: the architecture should fit, but no one has run the formulation yet. | peptide | MW | category | why it could fit | status | | --- | --- | --- | --- | --- | | insulin | 5,808 Da | metabolic | the canonical proof-of-concept. Cherian 2000 PMID:10769790 (https://pubmed.ncbi.nlm.nih.gov/10769790/) coated insulin-AQASOMEs with cellobiose, pyridoxal-5-phosphate or trehalose and reported better in vivo performance than a plain insulin solution, by the parenteral route. | proven in literature | | hemoglobin | 64,500 Da | oxygen carrier | established AQASOME payload in the 2010 Umashankar review PMID:19931422 (https://pubmed.ncbi.nlm.nih.gov/19931422/). proof that the architecture handles very large protein loads. | proven in literature | | serratiopeptidase | 45,000 Da | anti-inflammatory enzyme | oral delivery documented in the 2010 Umashankar peptide/protein AQASOME review PMID:19931422 (https://pubmed.ncbi.nlm.nih.gov/19931422/). another large-payload proof point. | proven in literature | | tesamorelin | 5,135 Da | GHRH analog (visceral fat) | GHRH analog with strong injectable data. larger than retatrutide but otherwise similar in shape and chemistry. should fit the AQASOME envelope with room to spare. | plausible: fits the envelope | | semaglutide | 4,113 Da | GLP-1 mono-agonist | rybelsus already proves oral semaglutide works at 0.4-2% via SNAC tech. AQASOME route would likely beat that ceiling. lilly + novo haven't tried this carrier in published work yet. | plausible: fits the envelope | | tirzepatide | 4,814 Da | GLP-1 + GIP dual agonist | same envelope as retatrutide. dual receptor agonist. if ion3r works for retatrutide, tirzepatide-in-AQASOME should work for the same reasons. | plausible: fits the envelope | | cagrilintide | 4,234 Da | amylin analog (appetite) | novo's long-acting amylin analog. similar MW + chemistry to retatrutide. companion to semaglutide in cagrisema trials. could pair well in an oral stack. | plausible: fits the envelope | | selank | 751 Da | anxiolytic / nootropic | already small enough to violate lipinski cleanly. could theoretically work orally without nano-encapsulation, but AQASOME carrier would protect against gastric degradation and potentially raise bioavailability. | plausible: fits the envelope | | semax | 813 Da | nootropic / BDNF upregulator | small heptapeptide. same logic as selank. published nasal route is the standard. oral via AQASOME is unstudied but mechanistically reasonable. | no data yet | | epitalon | 390 Da | telomerase / longevity | very small tetrapeptide, well under lipinski. published data is mostly russian + thin. AQASOME carrier could enable consistent oral dosing if the mechanism is real. | no data yet | | oxytocin | 1,007 Da | bonding / social | FDA-approved injectable + intranasal. peptide is small enough but extremely fragile. AQASOME carrier could enable a stable oral route, pharmaceutically interesting but commercially niche. | no data yet | | GHK-Cu | 340 Da + Cu | copper tripeptide | already in IonPeptide's lineup. listed here because the copper coordination chemistry is what made AQASOME valuable for this molecule specifically. | proven in literature | insulin 5,808 Da metabolic the canonical proof-of-concept. Cherian 2000 PMID:10769790 (https://pubmed.ncbi.nlm.nih.gov/10769790/) coated insulin-AQASOMEs with cellobiose, pyridoxal-5-phosphate or trehalose and reported better in vivo performance than a plain insulin solution, by the parenteral route. proven in literature hemoglobin 64,500 Da oxygen carrier established AQASOME payload in the 2010 Umashankar review PMID:19931422 (https://pubmed.ncbi.nlm.nih.gov/19931422/). proof that the architecture handles very large protein loads. proven in literature serratiopeptidase 45,000 Da anti-inflammatory enzyme oral delivery documented in the 2010 Umashankar peptide/protein AQASOME review PMID:19931422 (https://pubmed.ncbi.nlm.nih.gov/19931422/). another large-payload proof point. proven in literature tesamorelin 5,135 Da GHRH analog (visceral fat) GHRH analog with strong injectable data. larger than retatrutide but otherwise similar in shape and chemistry. should fit the AQASOME envelope with room to spare. plausible: fits the envelope semaglutide 4,113 Da GLP-1 mono-agonist rybelsus already proves oral semaglutide works at 0.4-2% via SNAC tech. AQASOME route would likely beat that ceiling. lilly + novo haven't tried this carrier in published work yet. plausible: fits the envelope tirzepatide 4,814 Da GLP-1 + GIP dual agonist same envelope as retatrutide. dual receptor agonist. if ion3r works for retatrutide, tirzepatide-in-AQASOME should work for the same reasons. plausible: fits the envelope cagrilintide 4,234 Da amylin analog (appetite) novo's long-acting amylin analog. similar MW + chemistry to retatrutide. companion to semaglutide in cagrisema trials. could pair well in an oral stack. plausible: fits the envelope selank 751 Da anxiolytic / nootropic already small enough to violate lipinski cleanly. could theoretically work orally without nano-encapsulation, but AQASOME carrier would protect against gastric degradation and potentially raise bioavailability. plausible: fits the envelope semax 813 Da nootropic / BDNF upregulator small heptapeptide. same logic as selank. published nasal route is the standard. oral via AQASOME is unstudied but mechanistically reasonable. no data yet epitalon 390 Da telomerase / longevity very small tetrapeptide, well under lipinski. published data is mostly russian + thin. AQASOME carrier could enable consistent oral dosing if the mechanism is real. no data yet oxytocin 1,007 Da bonding / social FDA-approved injectable + intranasal. peptide is small enough but extremely fragile. AQASOME carrier could enable a stable oral route, pharmaceutically interesting but commercially niche. no data yet GHK-Cu 340 Da + Cu copper tripeptide already in IonPeptide's lineup. listed here because the copper coordination chemistry is what made AQASOME valuable for this molecule specifically. proven in literature ## if you want to try this, here's where the only consumer brand commercializing AQASOME architecture across a full lineup right now is IonPeptide (https://www.bodyhackguide.co/go/ion). they shipped 11 SKUs in may 2026. BHG is a launch affiliate: clicking through one of the links below applies our ref code `reddit15` at checkout (discount for you, commission to BHG). disclosed in full at the bottom of the page. ion3r retatrutide 18mg view product→ https://www.bodyhackguide.co/go/ion-3r bpc-157 30mg drops view product→ https://www.bodyhackguide.co/go/ion-bpc-157 tb-500 30mg drops view product→ https://www.bodyhackguide.co/go/ion-tb-500 wolverine bpc-157 + tb-500 view product→ https://www.bodyhackguide.co/go/ion-wolverine glow \+ ghk-cu view product→ https://www.bodyhackguide.co/go/ion-glow ghk-cu 50mg drops view product→ https://www.bodyhackguide.co/go/ion-ghk-cu cjc-1295 30mg drops view product→ https://www.bodyhackguide.co/go/ion-cjc-1295 ipamorelin 30mg drops view product→ https://www.bodyhackguide.co/go/ion-ipamorelin pt-141 30mg drops view product→ https://www.bodyhackguide.co/go/ion-pt-141 slu-pp-332 30mg drops view product→ https://www.bodyhackguide.co/go/ion-slu-pp-332 aod-9604 30mg drops view product→ https://www.bodyhackguide.co/go/ion-aod-9604 Or browse the whole lineup see all 11 AQASOME drops at IonPeptide ionpeptide.com→ https://www.bodyhackguide.co/go/ion ## further reading on BHG - injectable retatrutide stack: https://www.bodyhackguide.co/blog/ultimate-shred-stack-retatrutide-tesamorelin-protocol - standalone retatrutide protocol: https://www.bodyhackguide.co/blog/retatrutide-protocol-guide-2026 - wolverine pair comparison: https://www.bodyhackguide.co/blog/bpc-157-vs-tb-500 - verify any oral product's COA: https://www.bodyhackguide.co/blog/how-to-read-peptide-coa - retatrutide vs tirzepatide: https://www.bodyhackguide.co/compare/retatrutide-vs-tirzepatide - retatrutide vendor prices: https://www.bodyhackguide.co/compound/retatrutide - peptide vendor trust scorecard: https://www.bodyhackguide.co/vendors/scorecard * * * **disclosure:** ion peptide is one of BHG's launch affiliate partners. /go/ion-* links are tracked and use the ref code `reddit15`: applies a discount for you at checkout and pays BHG a commission. IonPeptide sent samples for evaluation. not a paid post. the body copy was written before the affiliate relationship started. educational, not medical advice. peptides discussed are research compounds in most jurisdictions and are not FDA-approved for the uses described. retatrutide is investigational and only legally available via clinical trials as of may 2026. talk to a clinician before starting any peptide protocol. the BHG team Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) Shop BHG Labs 20% off your first order, code BHG20: https://bhglabs.co/shop/?ref=zmgqyxku&coupon=BHG20 ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Article", "headline": "how oral retatrutide gets past lipinski's rule: AQASOME nanotechnology explained", "description": "retatrutide is 4,895 daltons. lipinski's rule says nothing over 500 da gets absorbed orally. so how does the oral version work? AQASOME 3-layer nano-encapsulation, m-cell lymphatic uptake, and 34 years of published architecture.", "datePublished": "2026-05-20", "dateModified": "2026-05-20", "author": { "@type": "Organization", "name": "BodyHackGuide" }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/icon-512.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://www.bodyhackguide.co/blog/aqasome-nanotechnology-oral-peptides" } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "do oral peptides actually work?", "acceptedAnswer": { "@type": "Answer", "text": "free peptide in a capsule, no. wrapped in the right delivery system, yes. rybelsus (oral semaglutide) gets 0.4-2% bioavailability via snac chaperone technology and is a multi-billion-dollar product because that's enough drug. injected insulin-in-AQASOMEs shows documented systemic activity in vivo. oral insulin in polybutylcyanoacrylate nanoparticles reached 22.4% apparent bioavailability against an injection in diabetic rats." } }, { "@type": "Question", "name": "how can a peptide over 500 daltons be orally bioavailable?", "acceptedAnswer": { "@type": "Answer", "text": "lipinski's rule of 5 predicts absorption of free small molecules from the gut lumen across enterocyte membranes. it doesn't account for nanoparticle delivery via m-cells in peyer's patches and lymphatic uptake. cyclosporine (1,202 Da), rybelsus (4,113 Da), and monoclonal antibodies (~150,000 Da) all violate the rule and work clinically." } }, { "@type": "Question", "name": "what is AQASOME nanotechnology?", "acceptedAnswer": { "@type": "Answer", "text": "AQASOMEs are self-assembled 60-300 nm nanoparticles with three layers: a calcium phosphate or ceramic core, a polyhydroxy oligomer carbohydrate film (trehalose or cellobiose), and a bioactive payload (the peptide) adsorbed on the outer surface. first described by Kossovsky et al. in the early 1990s." } }, { "@type": "Question", "name": "how does oral retatrutide compare to rybelsus?", "acceptedAnswer": { "@type": "Answer", "text": "rybelsus uses snac (salcaprozate sodium) to transiently raise gastric ph and chaperone free semaglutide across the stomach lining, yielding 0.4-2% oral bioavailability per the FDA label. oral retatrutide-in-AQASOME packages the peptide on a nanoparticle that bypasses acid, proteases, and first-pass liver metabolism via m-cell lymphatic uptake. mechanically the AQASOME route has a higher bioavailability ceiling. per-compound pk data for the AQASOME-retatrutide formulation is not in peer-reviewed literature yet." } }, { "@type": "Question", "name": "what's the difference between the glow stack and the wolverine stack?", "acceptedAnswer": { "@type": "Answer", "text": "both contain bpc-157 and tb-500 for systemic recovery and tissue repair. glow adds ghk-cu (the copper peptide) for skin density, hair density, and collagen upregulation, making it the cosmetic and aesthetic-focused version. wolverine is the orthopedic and injury recovery version." } } ] } ] ```